Pain Management · OpioidRegulatory Approvalcommercialnear-term

FDA Grants Approval for Tramadol Hydrochloride ANDA209404 by Macleods

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Macleods Pharmaceuticals2 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 6:31:35 PM

Assessment confidence: 55% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Macleods' generic Tramadol Hydrochloride is significant as it introduces increased competition in the pain management market. This could lead to pricing pressures and shifts in market share among existing players, necessitating close observation of market dynamics. Regulatory context from FDA (FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 13 ranked evidence items (3 high-relevance).

Strategic Assessment

Macleods' entry into the market may pressure pricing and market share for existing Tramadol products from other manufacturers. The strongest clinical anchor is Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 8 regulatory and 2 competitive items passed relevance filtering for Macleods Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL) (FDA). Entity match (tramadol hydrochloride); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, but does not suggest immediate regulatory changes affecting other products.

Key Opportunities

The entry of Macleods into the Tramadol market may dilute the revenue of existing manufacturers due to potential price reductions and increased competition for market share.
Macleods' entry into the market may pressure pricing and market share for existing Tramadol products from other manufacturers.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and pricing strategies from Macleods and competitors.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (tramadol hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (tramadol hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (tramadol hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (tramadol hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (tramadol hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (tramadol hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (tramadol hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (tramadol hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source

Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Comparison of Two Dosing Regimens of Intravenous Ketorolac for Post-Cesarean Pain Control
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Prospective Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Chronic Low Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient
Merckmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
FDA Grants Priority Review for UTEBZI (TEBIPENEM, PIVOXIL) by GlaxoSmithKline
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
FDA Grants Approval for Eltrombopag Olamine ANDA208815
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Macleods Pharmaceuticals
Tramadol Hydrochloride
existing Tramadol manufacturers

Commercial impact

medium

The entry of Macleods into the Tramadol market may dilute the revenue of existing manufacturers due to potential price reductions and increased competition for market share.

Regulatory impact

low

The approval indicates compliance with FDA standards, but does not suggest immediate regulatory changes affecting other products.

What to watch

Monitor market entry timelines and pricing strategies from Macleods and competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.